<qa>  What is the placebo-controlled trial of atomoxetine?This study is a double-blind, placebo-controlled, parallel group trial of atomoxetine 1.8 mgkg for the management of chemotherapy-related acquired attentional disorders in children who have survived Acute Lymphocytic Leukemia. Atomoxetine will produce a favorable impact on ADHD symptoms in children with chemo-related acquired attentional disorders. 